Alterity Therapeutics Limited Stock Nasdaq
Stocks
ATHE
US02155X2053
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Nasdaq
00:30:00 17/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 3.850 USD | +10.00% |
|
-14.63% | +25.00% |
| Market Cap | 67.69M 58.66M 55.44M 50.33M 94.34M 6.49B 94.9M 662M 256M 3.29B 254M 249M 10.5B | P/E 2027 * |
-3.15x | P/E 2028 * | -0.39x |
|---|---|---|---|---|---|
| Enterprise Value | 26.79M 23.21M 21.94M 19.92M 37.33M 2.57B 37.56M 262M 101M 1.3B 101M 98.39M 4.15B | EV / Sales 2027 * |
56.3x | EV / Sales 2028 * | 15.4x |
| Free-Float |
97% | Yield 2027 * |
-
| Yield 2028 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| ATHE | Delayed | |
CBOE
| ATHE | Real-time | |
|
Deutsche Boerse AG
| PBN0 | Delayed | |
|
Börse Stuttgart
| PBN0 | Delayed |
Last Transcript: Alterity Therapeutics Limited
| 1 day | +10.00% | ||
| 1 week | -14.63% | ||
| Current month | -14.25% | ||
| 1 month | -19.62% | ||
| 3 months | -12.70% | ||
| 6 months | +6.94% | ||
| Current year | +25.00% |
| 1 week | 3.5 |  | 4.46 |
| 1 month | 3.5 | | 5.01 |
| Current year | 3.02 | | 5.89 |
| 1 year | 2.66 | | 5.89 |
| 3 years | 1 | | 7 |
| 5 years | 1 | | 13.9 |
| 10 years | 1 | | 51.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Stamler
CEO | Chief Executive Officer | 65 | 07/01/2021 |
| Director of Finance/CFO | - | 30/09/2024 | |
| Chief Tech/Sci/R&D Officer | - | 01/04/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
Peter Marks
BRD | Director/Board Member | 70 | 29/07/2005 |
Lawrence Gozlan
BRD | Director/Board Member | 47 | 08/08/2011 |
David Stamler
BRD | Director/Board Member | 65 | 21/11/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +10.00% | -14.63% | - | - | 66.89M | |
| +0.22% | -3.17% | -1.61% | +8.24% | 45.81B | |
| -4.36% | -5.50% | +324.07% | +516.88% | 43.91B | |
| -0.32% | +3.71% | +44.55% | +26.98% | 44.39B | |
| +0.46% | -0.97% | +4.76% | +73.76% | 39.4B | |
| -0.17% | -3.22% | +9.45% | +38.69% | 31.26B | |
| +3.30% | -8.29% | - | - | 15.75B | |
| -0.65% | +4.32% | +24.18% | +120.17% | 17.32B | |
| +1.66% | +4.92% | +18.42% | +34.93% | 14.73B | |
| +0.19% | -2.62% | +79.59% | +31.52% | 13.03B | |
| Average | +1.09% | -1.08% | +62.93% | +106.40% | 29.51B | |
| Weighted average by Cap. | -0.34% | -1.10% | +73.42% | +125.65% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 475K 412K 389K 354K 663K 45.61M 667K 4.65M 1.8M 23.13M 1.79M 1.75M 73.73M | 1.98M 1.71M 1.62M 1.47M 2.76M 190M 2.77M 19.34M 7.47M 96.26M 7.43M 7.27M 307M |
| Net income | -27.54M -23.87M -22.56M -20.48M -38.38M -2.64B -38.61M -269M -104M -1.34B -103M -101M -4.27B | -30.84M -26.73M -25.26M -22.94M -42.99M -2.96B -43.24M -302M -117M -1.5B -116M -113M -4.78B |
| Net Debt | -40.9M -35.45M -33.5M -30.41M -57M -3.92B -57.34M -400M -155M -1.99B -154M -150M -6.34B | -37.15M -32.2M -30.43M -27.63M -51.78M -3.56B -52.09M -363M -140M -1.81B -140M -136M -5.76B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/09/26 | $3.850 | +10.00% | 10,419 |
| 15/09/26 | $3.500 | -9.33% | 14,571 |
| 14/09/26 | $3.860 | -4.69% | 32,999 |
| 11/09/26 | $4.050 | -1.46% | 22,302 |
| 10/09/26 | $4.110 | -8.67% | 56,867 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ATH Stock
- ATHE Stock
Select your edition
All financial news and data tailored to specific country editions
